Park Place Capital Corp Acquires 915 Shares of Sanofi (NASDAQ:SNY)

Park Place Capital Corp boosted its stake in shares of Sanofi (NASDAQ:SNY) by 10.7% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 9,463 shares of the company’s stock after buying an additional 915 shares during the period. Park Place Capital Corp’s holdings in Sanofi were worth $545,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. POM Investment Strategies LLC bought a new stake in shares of Sanofi during the second quarter valued at approximately $25,000. Register Financial Advisors LLC acquired a new position in Sanofi during the first quarter valued at $29,000. Larson Financial Group LLC grew its holdings in Sanofi by 480.8% during the first quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock worth $29,000 after acquiring an additional 500 shares during the period. Palisade Asset Management LLC purchased a new stake in Sanofi during the first quarter worth $31,000. Finally, Arrow Financial Corp acquired a new position in Sanofi in the 2nd quarter worth about $35,000. Institutional investors own 10.04% of the company’s stock.

Sanofi Price Performance

Shares of SNY traded up $0.24 during trading hours on Tuesday, reaching $55.00. 442,416 shares of the company traded hands, compared to its average volume of 2,027,222. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $139.30 billion, a PE ratio of 27.52, a price-to-earnings-growth ratio of 1.58 and a beta of 0.60. The stock has a fifty day simple moving average of $55.58 and a 200 day simple moving average of $51.19. Sanofi has a fifty-two week low of $42.63 and a fifty-two week high of $58.97.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The firm had revenue of $10.75 billion for the quarter, compared to analysts’ expectations of $16.86 billion. During the same quarter last year, the firm earned $0.95 earnings per share. The firm’s revenue for the quarter was up 7.8% compared to the same quarter last year. As a group, research analysts predict that Sanofi will post 4.26 EPS for the current fiscal year.

Wall Street Analyst Weigh In

SNY has been the topic of a number of research reports. Citigroup raised shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Argus raised their price target on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Finally, StockNews.com raised shares of Sanofi from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, October 2nd. Three investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.